In ₹ Crore except Per Share Latest Annual | ALKEM FY26 | MANKIND FY26 | TORNTPHARM FY26 | IPCALAB FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | ◆ 26.55× | 48.46× | 77.05× | 43.84× | 48.46× -45% | |
| P/B | ◆ 4.26× | 5.60× | 9.48× | 5.25× | 5.60× -24% | |
| EV/EBITDA | ◆ 20.54× | 26.84× | 39.37× | 25.10× | 26.84× -23% | |
| Market Cap | ₹61,102 Cr | ₹92,715 Cr | ₹1.67L Cr | ₹50,032 Cr | ₹92,715 Cr -34% | |
| Growth | ||||||
| Revenue CAGR 3Y | 8.25% | ◆ 17.73% | 13.27% | 15.60% | 15.60% -47% | |
| Revenue CAGR 5Y | 10.09% | — | 11.80% | ◆ 12.22% | 12.01% -16% | |
| Net Income CAGR 3Y | 32.67% | 13.96% | 19.75% | ◆ 35.20% | 19.75% +65% | |
| Revenue YoY (latest Q) | 10.95% | 12.89% | ◆ 54.85% | 20.76% | 20.76% -47% | |
| Net Income YoY (latest Q) | -22.00% | 29.12% | 3.28% | ◆ 82.18% | 29.12% -176% | |
| Profitability | ||||||
| EBITDA Margin | 20.43% | 25.34% | ◆ 32.61% | 20.51% | 25.34% -19% | |
| Net Income Margin | ◆ 15.98% | 13.57% | 15.29% | 12.27% | 13.57% +18% | |
| Return on Common Equity | ◆ 16.04% | 11.55% | 12.30% | 11.98% | 11.98% +34% | |
| Return on Capital Employed | ◆ 16.30% | 12.66% | 9.56% | 15.51% | 12.66% +29% | |
| Return on Assets | ◆ 11.26% | 6.90% | 4.82% | 9.57% | 6.90% +63% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.11× | 0.38× | 0.84× | ◆ 0.07× | 0.38× -71% | |
| Interest Coverage | 16.32× | 4.27× | 8.94× | ◆ 20.55× | 8.94× +83% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹14,712 Cr | ₹14,278 Cr | ₹13,980 Cr | ₹9,646 Cr | ₹13,980 Cr +5% | |
| Net Income | ₹2,351 Cr | ₹1,938 Cr | ₹2,138 Cr | ₹1,184 Cr | ₹1,938 Cr +21% | |
| Total Assets | ₹20,873 Cr | ₹28,080 Cr | ₹44,312 Cr | ₹12,370 Cr | ₹28,080 Cr -26% | |
| EPS | ₹192.51 | ₹46.35 | ₹63.92 | ₹44.98 | ₹46.35 +315% | |
| Book Value per Share | ₹1,200.25 | ₹401.19 | ₹519.56 | ₹375.41 | ₹401.19 +199% | |